Your session is about to expire
← Back to Search
Other
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called AMG 256 in adults to see if it is safe and to find the best dose for future studies.
Eligible Conditions
- Advanced Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Dose Expansion Phase: Group 2Experimental Treatment1 Intervention
Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
Group II: Dose Expansion Phase: Group 1Experimental Treatment1 Intervention
Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
Group III: Dose Escalation PhaseExperimental Treatment1 Intervention
Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 256
2020
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
AmgenLead Sponsor
1,442 Previous Clinical Trials
1,397,710 Total Patients Enrolled
MDStudy DirectorAmgen
980 Previous Clinical Trials
941,466 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have cancer that has spread and cannot be treated with surgery or radiation. You have already tried standard treatments, but they have not worked, are not available, or are not expected to help you.
Research Study Groups:
This trial has the following groups:- Group 1: Dose Escalation Phase
- Group 2: Dose Expansion Phase: Group 1
- Group 3: Dose Expansion Phase: Group 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.